Current concepts and perspectives of immunosuppression in organ transplantation.

Langenbecks Arch Surg 2007 Sep 21;392(5):511-23. Epub 2007 Apr 21.

Klinik und Poliklinik für Chirurgie und Transplantation, Klinikum der Universität Regensburg, Franz-Josef-Strauss-Allee 11, 93042, Regensburg, Germany.

Background: While early surgical success made organ transplantation possible in the 1950s and 1960s, the breakthrough in clinical organ transplantation was achieved through the discovery and invention of modern immunosuppressive agents in the early/mid-1980s. Especially during the 1990 s, a large array of immunosuppressants has expanded the armamentarium used to prevent and treat allograft rejection, resulting in an excellent short-term and an acceptable long-term outcome. However, these drugs have potent but still non-specific immunosuppressive properties and frequently show severe acute and chronic side effects, sometimes questioning the overall success.

Concepts/trends: As the "Holy-Grail" of the transplant community, the induction of "true donor-specific tolerance" has not been achieved yet; current immunosuppressive strategies, in particular in Europe, include "individually tailored immunosuppressive" protocols, mostly based on specific immunologic and non-immunologic risk factors. These protocols allow for optimal immunosuppressive protocols for each patient group according to their needs by choosing the most suitable, well-tolerated combination of agents and the most effective doses to avoid acute rejection episodes (incidence and severity) and minimise drug-related toxicity to reduce long-term drug-related morbidity and mortality. Nevertheless, transplant recipient are still being forced to take a life-long course of chemical immunosuppressive agents to keep their graft, knowing about the possible life-threatening side effects.

Summary: We review current trends of immunosuppressive protocols in liver and kidney transplantation, focusing on calcineurin-inhibitor-sparing protocols, mammalian-target-of-rapamycin (mTOR) inhibitor based-protocols and corticosteroid-avoidance protocols, being aware of the fact, that most of these strategies could be applicable for other transplanted organs, too. Finally, we describe future trends and new developments that are rising on the horizon.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00423-007-0188-zDOI Listing
September 2007
3 Reads

Publication Analysis

Top Keywords

organ transplantation
12
immunosuppressive agents
8
immunosuppressive protocols
8
protocols
6
immunosuppressive
6
include "individually
4
trends immunosuppressive
4
"individually tailored
4
europe include
4
protocols liver
4
immunosuppressive strategies
4
strategies europe
4
current trends
4
tailored immunosuppressive"
4
specific immunologic
4
protocols based
4
review current
4
effectssummary review
4
current immunosuppressive
4
immunologic non-immunologic
4

References

(Supplied by CrossRef)

Y Calmus et al.
Liver Transplant 2002

P Neuhaus et al.
Liver Transplant 2002

SJ Knechtle et al.
Am J Transplant Jun 2003

SJ Knechtle et al.
Surgery 2004

DD Bloom et al.
Transplantation 2006

JF Magliocca et al.
Transpl Int 2006

SJ Knechtle et al.
Nat Clin Pract Nephrol Dez 2005

RN Barth et al.
Transpl Int 2006

PJ Morris et al.
Transplantation 2006

R Calne et al.
Lancet 1998

R Calne et al.
Transplantation 1999

Similar Publications